JNJ vs MRNA
By Alex · Tickerpine
Johnson & Johnson vs Moderna, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | JNJ | MRNA |
|---|---|---|
| Price | $263.81 | $200.10 |
| Market cap | $635.07B | $79.89B |
| P/E ratio | 40.0 | — |
| ROE | 20.02% | -39.00% |
| Profit margin | 16.20% | -141.43% |
| Revenue growth | 5.90% | 2.10% |
| Dividend yield | 2.03% | 0.00% |
| Beta | 0.21 | 1.09 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
JNJ vs MRNA in plain English
- JNJ is the bigger company — about 7.9× the market cap of MRNA.
- JNJ earns a higher return on equity (20% vs -39%).
- JNJ is growing revenue faster (6% vs 2%).
- JNJ pays a dividend (2.03%) while the other effectively doesn't.
How would $1,000 have done in each?
JNJ return calculator
See what $1,000 in Johnson & Johnson would be worth today.
MRNA return calculator
See what $1,000 in Moderna, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.